Quick Take: AstraZeneca Pursues Traditional Chinese Medicine As New Source For R&D
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca signs research collaboration with Shanghai’s Fudan University to investigate mechanism of action for a TCM compound to treat cardiovascular disease.
You may also be interested in...
Sanofi-Aventis Asia Pacific R&D Head Frank Jiang On Opportunities In China And India: An Interview With PharmAsia News (Part 1 of 2)
Sanofi-Aventis VPand Head, Asia PacificR&D Frank Jiang talked to PharmAsia News along the sidelines of the recent DIA China conference in Beijing. Jiang shared his vision of how the company is revamping its R&D strategies in Asia to bring more therapies to patients in India and China.
Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 2 of 2)
[Editor's Note: This is part two of a two-part interview. Part one appeared May 4, 2008 in PharmAsia News.]
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.